USA flag logo/image

An Official Website of the United States Government

TGFb1 Receptor Inhibitors for Liver Fibrosis

Award Information

Department of Health and Human Services
Award ID:
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2008
Title: TGFb1 Receptor Inhibitors for Liver Fibrosis
Agency: HHS
Contract: 1R43DK080549-01
Award Amount: $255,501.00


DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease ass ociated with non-alcoholic steatohepatitis. Currently available therapies, including antivirals, are largely ineffective in treating the underlying fibrosis, and in the majority of cases, liver transplantation is the only effective cure. Liver fibrosis, ir respective of its etiology, reflects the same cellular and molecular pathophysiology. Activation of hepatic stellate cells and conversion to myofibroblasts is the dominant event in fibrogenesis, and proceeds along a continuum that involves progressive chan ges in cellular function. The cytokine TGF?1 plays a central role in stellate cell activation and fibrosis. TGF?1 binds to and activates its receptor (ALK5), which phosphorylates and activates signaling proteins including Smad2, resulting in expression of upregulation of fibrotic marker genes, such as ?SMA. Our long-term goal is the development of small molecule inhibitors of the TGF?1 receptor as potential therapeutics for fibrotic liver disease. The objective of this application is to identify suc h inhibitors and evaluate them in two clinically relevant animal models of liver fibrosis. Small molecule inhibitors of the TGF?1 receptor are potential therapeutics for fibrotic disease in the liver, as well as other major organs.

Principal Investigator:

Weizhong Cai

Business Contact:
Small Business Information at Submission:

ANGION BIOMEDICA CORP 1050 Stewart Ave. Garden City, NY 11530

EIN/Tax ID: 113430072
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No